Stock Movers

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study.
- Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity incident has impacted its ability to ship its products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year.
- Intel (INTC) is rising on a report that the company could raise computer chip prices next month.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study.
- Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity incident has impacted its ability to ship its products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year.
- Intel (INTC) is rising on a report that the company could raise computer chip prices next month.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Novartis suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. Novartis shares plunged as much as 10% in early Zurich trading, reducing their gain for the year to about 4%, trailing rival Roche.
- Computacenter shares climb as much as 7.4%, reaching a record high, after the IT services company upgraded its profit before tax guidance for fiscal year 2026 once again, after doing so at its July trading update. The group also reported a revenue beat in the first half, driven by strong AI-related spend in the US.
- Rubis shares rise as much as 5.3% after the energy solutions firm boosted its Ebitda guidance for the full year.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Novartis suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. Novartis shares plunged as much as 10% in early Zurich trading, reducing their gain for the year to about 4%, trailing rival Roche.
- Sandoz nudged up its mid-term guidance and set a goal of increasing the number of biosimilars in its portfolio to more than 100 by 2040, from 13 currently.
- Computacenter shares climb as much as 7.4%, reaching a record high, after the IT services company upgraded its profit before tax guidance for fiscal year 2026 once again, after doing so at its July trading update. The group also reported a revenue beat in the first half, driven by strong AI-related spend in the US.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Samsung's anticipated equity buyback is raising investor expectations that the Korean giant will buy up non‑voting preferred shares, narrowing a steep discount and setting an example for others.
- Asia PC maker shares drop after a report that Intel plans to raise personal computer CPU prices by another 10% as early as next month.
- An experimental lung disease drug developed using artificial intelligence showed promise in reversing biological signs of ageing, pointing to broader potential use of the treatment, according to its developer. Insilico’s shares jumped as much as 10% on Tuesday, the most since August 25th.
See omnystudio.com/listener for privacy information.